AthemBio is a private biotechnology company based in Research Triangle Park, NC, dedicated to solving the most challenging hurdles in bioprocessing. Our mission is to make advanced, life-saving therapies and vaccines accessible to all by overcoming the excessive manufacturing expenses that act as a barrier to patient access.
We provide groundbreaking, next-generation bioprocessing platforms that simplify workflows, eliminate manufacturing bottlenecks, and feature a significantly smaller physical footprint. By empowering vaccine and biologic manufacturers to transition away from complex, multi-step batch processing, AthemBio helps scale production efficiently from early discovery to commercial manufacturing.
Our revolutionary, single-use product portfolio includes CORIg™ (the first single-use centrifuge with true continuous discharge for gentle, high-recovery separation), cRUSH™ (a continuous, detergent-free mechanical cell lysis system ideal for microbial cells and viral vectors), and machroS™ (a direct affinity capture technology based on non-porous nanoparticles that bypasses traditional clarification steps).
To meet the rigorous demands and rapid scalability required in modern vaccine production, all AthemBio solutions are built on a core next-generation design philosophy:
Automated & Continuous: We drastically reduce manufacturing steps and replace inefficient intermittent processes to accelerate your workflow.
Single-Use & Closed: Our closed-system designs completely eliminate cleaning downtime and cross-contamination risks, ensuring the highest standards of safety and compliance.
Efficient & Compact: We maximize throughput per square foot, offering highly scalable performance without the need for massive facility expansions.
Non-Invasive Sensing: Fully integrated, real-time monitoring through non-invasive sensors guarantees precise process control while reducing the cost of disposable assemblies.
Whether you are streamlining process development or scaling up commercial vaccine manufacturing, AthemBio is your partner in driving down costs and ensuring that critical therapies reach the patients who need them most.